** Shares of Avadel Pharmaceuticals AVDL.O fall ~25% to $8.01 premarket
** Late on Wednesday AVDL forecast 2025 rev in the range of $240 mln to $260 mln
** Analysts on average estimate total revenue of about $267.6 mln -LSEG data
** At least two brokerages cut PT on AVDL following the disappointing 2025 outlook
** H.C.Wainwright analysts expect a slower revenue ramp up for its sleep disorder drug Lumryz
** Up to last close, stock down ~32% over the past 12 months
(Reporting by Mariam Sunny in Bengaluru)
((Mariam.ESunny@thomsonreuters.com;))
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.